baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

GSK plc/ US37733W2044 /

2024-05-15 4:55:21 PM	Chg. +0.13	Volume	Bid4:55:25 PM	Ask4:55:25 PM	High	Low
45.79USD	+0.28%	1.13 mill. Turnover: 46.06 mill.	45.78Bid Size: 500	45.79Ask Size: 1,700	45.91	45.69

GlobeNewswire 05-13 Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...

GlobeNewswire 05-10 iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire 05-10 iTeos Therapeutics Announces $120 Million Registered Direct Offering

GlobeNewswire 05-09 Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 05-09 Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) ...

GlobeNewswire 05-09 Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sag...

GlobeNewswire 05-09 Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 05-09 Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer

GlobeNewswire 05-09 Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

GlobeNewswire 05-08 SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire 05-08 Alector Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 05-08 Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wed...

GlobeNewswire 05-08 Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in ...

GlobeNewswire 05-07 BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Roun...

GlobeNewswire 05-01 Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TeleTrader 05-01 British FTSE 100 opens higher amid data, eyes on Fed

TeleTrader 05-01 GSK: Q1 revenue increases 6% to £7.3 billion

GlobeNewswire 04-30 SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the Euro...

GlobeNewswire 04-30 Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial o...

GlobeNewswire 04-29 Immutep Quarterly Activities Report Q3 FY24

GlobeNewswire 04-25 Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes ...

GlobeNewswire 04-23 Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and R...

GlobeNewswire 04-22 Kynos Therapeutics announces positive top-line results from the first-in-human Phase I study of its ...

GlobeNewswire 04-15 Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer

GlobeNewswire 04-10 Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atop...

GSK plc/ US37733W2044 /

If you wish to receive reply to your feedback, please provide your email address.